Latest Biotech News

Bayer reported Phase 3 results showing its Factor XIa inhibitor asundexian lowered the risk of secondary ischemic stroke by 26% without increasing bleeding, positioning the oral agent as a...

uniQure halted mid‑ and high‑dose cohorts in its AAV gene‑therapy trial for Fabry disease after two patients experienced grade‑3 liver enzyme elevations. The company reported the safety events and...

Adaptive Biotechnologies forecasted at least 20% MRD revenue growth for 2026, driven by ClonoSeq uptake, EMR integrations, and broader clinical endorsement of minimal residual disease as a...

A Nature Communications study identified succinate receptor 1 (SUCNR1) as a metabolic sentinel that limits blood cell formation and impedes acute myeloid leukemia (AML) progression. The...

Researchers reported a mussel‑inspired bioadhesive patch that selectively adheres to glioblastoma tissue and delivers cytotoxic agents to eliminate tumor cells in preclinical models. The platform...

Insilico Medicine announced ISM5059, a peripheral‑restricted NLRP3 inhibitor, as a nominated preclinical candidate following AI‑driven design and preclinical validation. The company emphasized the...

UniQure paused mid- and high-dose cohorts in its AAV gene‑therapy study for Fabry disease after patients developed dose-limiting liver toxicities. The company reported grade‑3 liver enzyme...

The White House launched TrumpRx, a direct‑to‑consumer drug purchasing platform that lists cash prices and discounts for a limited slate of medicines, but early reports show minimal impact on...

Telehealth provider Hims & Hers began offering a compounded oral version of Novo Nordisk’s Wegovy, prompting Novo to threaten legal action and the FDA to signal enforcement against unapproved...

Bayer reported Phase 3 data showing its Factor XIa inhibitor asundexian reduced secondary ischemic stroke risk by about 26% without increasing major bleeding, positioning the oral anticoagulant as...

Eikon Therapeutics completed an upsized $381 million IPO to bankroll clinical development of its oncology pipeline, including its TLR7/8 co‑agonist EIK‑1001 and PARP‑focused programs. The company,...

Illumina reported flat full‑year revenue for 2025 but flagged a notable acceleration in clinical sequencing consumables and an uptick in NovaSeq X placements. Management pointed to demand in...

Adaptive Biotechnologies set 2026 guidance expecting 20–30% growth in its minimal residual disease (MRD) business, driven by broader ClonoSeq adoption across hematologic malignancies, higher test...

ARPA‑H cut approximately 20 employees and contractors from roles tied to operations and commercialization, according to multiple sources and an HHS confirmation. The agency said scientific staff...

Flagship Pioneering‑backed Generate:Biomedicines filed for an IPO, spotlighting its AI‑engineered candidates including an anti‑TSLP program entering Phase 3 and other antibody and CAR‑T assets....

Priovant Therapeutics, a Roivant spinout, reported that brepocitinib — a TYK2/JAK1 inhibitor obtained from Pfizer — significantly outperformed placebo in a small Phase 2 study of cutaneous...

Bayer reported Phase 3 results showing its Factor XIa inhibitor asundexian reduced the risk of secondary ischemic stroke by 26% without increasing major bleeding. The data, presented by Bayer and...

UniQure paused mid- and high-dose cohorts in its Fabry gene therapy trial after two patients at 4x10^13 gc/kg experienced grade 3 liver enzyme elevations, the company said in a safety update. The...

Adaptive Biotechnologies projected at least 20% year-over-year MRD revenue growth for 2026, driven by increased adoption of its ClonoSeq minimal residual disease assay across oncology settings and...

Illumina reported flat full‑year 2025 revenue but a meaningful uptick in clinical sequencing consumables, which management said rose on increased uptake of sequencing‑based diagnostics including...